October 2022
The global specialty enzymes market size accounted for USD 6.16 billion in 2024, grew to USD 6.58 billion in 2025, and is expected to be worth around USD 11.89 billion by 2034, poised to grow at a CAGR of 6.8% between 2024 and 2034. The North America specialty enzymes market size is predicted to increase from USD 2.59 billion in 2024 and is estimated to grow at the fastest CAGR of 6.92% during the forecast year.
The global specialty enzymes market size is expected to be valued at USD 6.16 billion in 2024 and is anticipated to reach around USD 11.89 billion by 2034, expanding at a CAGR of 6.8% over the forecast period from 2024 to 2034.
The U.S. specialty enzymes market size is exhibited at USD 1.81 billion in 2024 and is projected to be worth around USD 3.56 billion by 2034, growing at a CAGR of 7% from 2024 to 2034.
In 2023, North America dominated the specialty enzymes market and was expected to grow faster during the forecast period due to its primary application in the feed and food sector. The region's growing intake of meat and meat products has increased the need for enzymes in the feed industries.
Growing consumption of processed food products increased spending on high-quality products, and customer inclination for natural raw materials used in the products is driving the market. Enzymes are natural additives added to food products to increase yield productivity, value performance, and shelf life.
Market Overview
Specialty enzymes are proteins that act as biocatalysts in pharmaceutical and diagnostic reactions to increase the rate of responses and desired outcomes. Specialty enzymes, which include carbohydrases, proteases, lipases, polymerases & nucleases, and others, are applied in different applications, including pharmaceuticals, research & biotechnology, diagnostics, and biocatalysts. The market's growth is estimated to drive by the new product launches by the market participants. For instance, in April 2022, specialty enzymes & probiotics launched two new products-ProbioSEB, CSC3 PET and ImmunoSEB PET.
Report Coverage | Details |
Market Size in 2024 | USD 6.16 Billion |
Market Size by 2034 | USD 11.89 Billion |
Growth Rate from 2024 to 2034 | CAGR of 6.8% |
Largest Market | North America |
Base Year | 2023 |
Forecast Period | 2024 to 2034 |
Segments Covered | By Type, By Application, and By Source |
Regions Covered | North America, Europe, Asia-Pacific, Latin America and Middle East & Africa |
Enzyme-based pharmaceutical drug formulations to treat diseases
Several drugs or pharmaceutical formulations contain active pharmaceutical ingredients (APIs) synthesised using enzymes as important manufacturing components. Enzyme therapy uses enzymes to treat enzyme deficiencies and other medical conditions in humans. Enzymes help humans digest food, detoxify the body, strengthen the immune system, contract muscles, and reduce stress on vital organs such as the pancreas.
Enzyme therapy has a wide range of potential medical applications, including treating pancreatic insufficiency and cystic fibrosis (CF), metabolic disorders, lactose intolerance, the removal of dead tissues, cancers, or tumors, and so on. The therapy can be systemic or nonsystemic and can be delivered via various routes, most commonly orally, topically, or intravenously. Enzymes are also used as digestive aids to cure digestive issues, including some sugar.
Technical barrier
Biocatalysis is a method of accelerating chemical reactions by utilising biomolecules. It contains conditions of moderate reaction and high-level selectiveness. As a result, specialty enzymes are essential in the chemical industry and are increasingly accepted in the industrial sector. However, determining the precise protein building of specialty enzymes is difficult. The procedure is time-intensive and necessitates using additional catalysts to meet the needs of the chemical reaction procedure. Conditions, such as new concentration, new substrate, and other terms not readily found in nature, are required to manufacture these enzymes. Due to these unresolved issues, specialty enzymes are unpredictable. As a result, more research and development are needed to produce enzymes in large quantities, creating an obstacle to the growth of the specialty enzymes market.
Rising investments
Rising spending in biotechnology R&D is anticipated to propel market growth during the forecast period. Specialty enzymes are commonly used in biotech research and development, especially in molecular biology. The rise in capital and the companies performing biotechnology research and development will raise several biotech researchers.
For instance, by April 2021, pharmaceutical companies will have spent $83 billion on research and development activities worldwide, according to a report published by the Congressional Budget Office. This US-based government agency provides budget and financial information. Healthcare is engaged in 49% of the more than 700 biotech firms headquartered in Italy, according to the Assobiotec publication BioInItaly 2020. Thus, there is a rise in biotech research companies' growing investments in biotech R&D is expected to boost the specialty enzymes market.
Based on type, the global specialty enzymes market is segmented into carbohydrases, proteases, proteases, lipases, polymerases & Nucleases, and other enzymes. In 2023, the carbohydrases segment accounted for the highest market share. carbohydrase is widely used as an ingredient and a processing aid in various industries, including food and beverage and pharmaceuticals. Cellulases and amylases are two significant carbohydrase enzyme variants. Rising sports drink demand is boosting the growth of this segment as it has cleansing properties. Carbohydrase is extensively used in detergents; therefore, its rising use of detergents in industrial and domestic applications is expected to propel the growth of this segment.
The potential use of carbohydrase inhibitors isolated from chestnuts to cure diabetes and obesity is anticipated to offer market players numerous prospects. Carbohydrase generates pH and temperature fluctuations. Such issues confronting the enzyme are expected to drive demand for potential substitutes, which may pose market challenges.
Based on the application, the global specialty enzymes market is segmented into pharmaceuticals, research & biotechnology, diagnostics, and biocatalysts. In 2023, the pharmaceutical industry accounted for the highest market share. The use of specialty enzymes in the pharmaceutical industry is primarily for drug manufacturing, disease diagnostics, and therapy.
The rising embedding of enzymes in treatments for diseases such as cancer, cardiovascular diseases, lysosomal storage disorders, and pain and inflammation management, among many others, is a factor that fuels market demand. In the pharmaceutical industry, specialty enzymes play a significant role in a wide range of applications across several therapeutic modalities, most notably for modification, but also to reduce viscosity and thus improve processability and to attach and de-attach cells, thereby increasing productivity. Enzymes are used in the pharmaceutical industry for group protection and deprotection, selective acylation and deacylation, selective hydrolysis, deracemisation, racemic mixture kinetic resolution, esterification, transesterification, and a variety of other reactions.
Based on the source, the global specialty enzymes market is segmented into microorganisms, plants, and animals. In 2023, the microorganisms segment accounted for the highest market share. The increasing use of amylases in the biotechnology and pharmaceutical industries will drive the growth of the microorganism-derived specialty enzymes market. Microbial enzymes are used in various industries, including chemical, fermentation, agricultural, pharmaceutical, and food production.
The decision of expression systems is critical for the rate of enzyme production, and bacteria, filamentous fungi, and yeasts have all been used to express recombinant enzymes. Because of the benefits of these species, the number of biotechnological applications has increased. However, physiological constraints make a high-level expression of recombinant enzymes difficult.
Natural enzymes have limitations, particularly under industrial conditions, such as low catalytic efficiency, activity, and stability. Strategies such as site-directed mutagenesis, truncation, and terminal fusion have overcome these constraints. Microbial enzymes are vital for medical treatments as they are inexpensive, consistent, and simple to isolate. The main advantage of microbial enzyme production is that it quickly yields high yields on low-cost media. These factors are expected to boost the segment's growth potential over the forecast period.
Segment Covered in the Report
By Type
By Application
By Source
By Geography
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
October 2022
November 2024
December 2022
November 2024